One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients.
Absorbable Implants
Aged
Aged, 80 and over
Anticoagulants
Death
Drug-Eluting Stents
/ adverse effects
Everolimus
/ adverse effects
Female
Hemorrhage
/ chemically induced
Humans
Myocardial Infarction
/ etiology
Percutaneous Coronary Intervention
/ adverse effects
Platelet Aggregation Inhibitors
/ adverse effects
Polymers
Prospective Studies
Thrombosis
/ etiology
Treatment Outcome
Synergy stent
bioresorbable polymer stent
coronary artery disease
high bleeding risk
percutaneous coronary intervention
short DAPT
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
pubmed:
5
2
2022
medline:
9
4
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
Background It is unknown whether contemporary drug-eluting stents have a similar safety profile in high bleeding risk patients treated with 1-month dual antiplatelet therapy following percutaneous coronary interventions. Methods and Results We performed an interventional, prospective, multicenter, single-arm trial, powered for noninferiority with respect to an objective performance criterion to evaluate the safety of percutaneous coronary interventions with Synergy bioresorbable-polymer everolimus-eluting stent followed by 1-month dual antiplatelet therapy in patients with high bleeding risk. In case of need for an oral anticoagulant, patients received an oral anticoagulant in addition to a P2Y
Identifiants
pubmed: 35114814
doi: 10.1161/JAHA.121.023454
pmc: PMC9075308
doi:
Substances chimiques
Anticoagulants
0
Platelet Aggregation Inhibitors
0
Polymers
0
Everolimus
9HW64Q8G6G
Banques de données
ClinicalTrials.gov
['NCT03112707']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e023454Commentaires et corrections
Type : ErratumIn
Références
N Engl J Med. 2001 Aug 16;345(7):494-502
pubmed: 11519503
N Engl J Med. 2016 Dec 22;375(25):2423-2434
pubmed: 27959713
N Engl J Med. 2020 Mar 26;382(13):1208-1218
pubmed: 32050061
Circulation. 2012 Oct 16;126(16):2020-35
pubmed: 22923432
Circulation. 2021 Feb 9;143(6):583-596
pubmed: 33555916
N Engl J Med. 2007 Nov 15;357(20):2001-15
pubmed: 17982182
N Engl J Med. 2021 Oct 28;385(18):1643-1655
pubmed: 34449185
Eur Heart J. 2009 Jun;30(12):1457-66
pubmed: 19351691
Circulation. 2019 Jul 16;140(3):240-261
pubmed: 31116032
Eur Heart J. 2017 Mar 14;38(11):804-810
pubmed: 28363222
Lancet. 2018 Jan 6;391(10115):41-50
pubmed: 29102362
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Circulation. 2021 Oct 12;144(15):1196-1211
pubmed: 34455849
JACC Cardiovasc Interv. 2021 Sep 13;14(17):1870-1883
pubmed: 34503737
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
Catheter Cardiovasc Interv. 2016 Sep;88(3):E67-73
pubmed: 26526783
Circ Cardiovasc Interv. 2015 Jun;8(6):e002427
pubmed: 26022535
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Eur Heart J. 2011 Dec;32(23):2933-44
pubmed: 22090660
N Engl J Med. 2015 Nov 19;373(21):2038-47
pubmed: 26466021
Eur Heart J. 2015 Oct 7;36(38):2608-20
pubmed: 26071600
Lancet. 2013 Mar 30;381(9872):1107-15
pubmed: 23415013
N Engl J Med. 2017 Oct 19;377(16):1513-1524
pubmed: 28844193
JACC Cardiovasc Interv. 2016 Mar 14;9(5):426-36
pubmed: 26965932
J Am Coll Cardiol. 2008 May 27;51(21):2028-33
pubmed: 18498956
Catheter Cardiovasc Interv. 2015 Nov 15;86(6):E247-57
pubmed: 26009986
Circ Cardiovasc Interv. 2019 Feb;12(2):e007311
pubmed: 30767663
Int J Cardiol. 2018 Jun 1;260:36-41
pubmed: 29622449
Circulation. 2018 Jun 12;137(24):2635-2650
pubmed: 29891620
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
J Am Coll Cardiol. 2020 Sep 22;76(12):1468-1483
pubmed: 32943165
Circ Cardiovasc Interv. 2021 Mar;14(3):e010144
pubmed: 33641374